Current therapeutic treatments (surgery, radiation, chemotherapy or a combination thereof) are ineffective in increasing survival of patients with advanced stages of squamous carcinomas. New therapeutic directions are needed and differentiation based therapy has been proposed to be one such avenue. This project is aimed at characterizing and determining the efficacy of a multicellular tumor spheroid (MTS) model as a preclinical tool for studying differentiation therapy of squamous carcinomas. In this model tumor cells grow in three dimensions and MTSs that exhibit both morphological and biochemical evidence for squamous differentiation and MTSs that are undifferentiated will be used. Changes in proliferation (growth studies, DNA synthesis, Ki-67 nuclear antigen expression) and differentiation markers (involucrin, filaggrin, keratin, transglutaminase, cornified envelopes) will be determined using biochemical, immunological and immunohistochemical techniques with MTSs of increasing size (initial dia. 250-300, 550-600, greater than 1000 mm). Subsequently, MTS studies will use differentiation modulating agents which are currently being evaluated in clinical trials and which are also known to either suppress the squamous phenotype (retinoids) or induce it (interferons). Drug induced effects on growth and differentiation will be determined. Additionally, individual cell proliferative potentials will be determined through MTS clonogenity and outgrowth studies, labeling index and flow cytometric analyses. Our hypothesis for the model is that if differentiation were induced, MTS growth should be decreased, differentiation markers increased, and proliferatively, individual cells should exit the cell cycle (increase in G1 population) and differentiate. Parallel drug penetration studies will define the potential diffusion barrier in this tissue-like model and liposomes will be examined as a delivery system to overcome any diffusion problems. In corollary to the MTS model, monolayer cultures will be similarly examined. A newly observed effect of retinoids (i.e. continuing cell proliferation in what appears to be a growth inhibited state, mechanistically related to RA induced cell death) will be examined in more detail to understand the universality of the phenomenon and the kinetics and mechanisms of cell death; the potential of combination therapy with cytotoxic agents will also be investigated to take advantage of the continuing cellular proliferation. With other differentiation agents. combination therapy will also be investigated to determine whether cytotoxicity can be potentiated through modulation of SCC differentiation status. Once established, the system could be used to identify agents with potential therapeutic activity in modulating squamous differentiation and as a system to investigate basic mechanisms associated with drug induced differentiation. Using such modulators of differentiation, these models could provide preclinical evaluation of agents for extension of differentiation-oriented ongoing clinical trials in our institution.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
5R01CA057166-03
Application #
2097926
Study Section
Experimental Therapeutics Subcommittee 1 (ET)
Project Start
1991-09-30
Project End
1995-08-31
Budget Start
1993-09-01
Budget End
1995-08-31
Support Year
3
Fiscal Year
1993
Total Cost
Indirect Cost
Name
Sloan-Kettering Institute for Cancer Research
Department
Type
DUNS #
064931884
City
New York
State
NY
Country
United States
Zip Code
10065
Spingarn, A; Sacks, P G; Kelley, D et al. (1998) Synergistic effects of 13-cis retinoic acid and arachidonic acid cascade inhibitors on growth of head and neck squamous cell carcinoma in vitro. Otolaryngol Head Neck Surg 118:159-64
Gillenwater, A; Xu, X C; Estrov, Y et al. (1998) Modulation of galectin-1 content in human head and neck squamous carcinoma cells by sodium butyrate. Int J Cancer 75:217-24
Kelley, D J; Mestre, J R; Subbaramaiah, K et al. (1997) Benzo[a]pyrene up-regulates cyclooxygenase-2 gene expression in oral epithelial cells. Carcinogenesis 18:795-9
Sacks, P G; Amos, B; Lotan, R (1996) Enhancement of glycosylation of cellular glycoconjugates in the squamous carcinoma cell line MDA886Ln by beta-all-trans retinoic acid. Glycoconj J 13:791-6
Sacks, P G; Harris, D; Chou, T C (1995) Modulation of growth and proliferation in squamous cell carcinoma by retinoic acid: a rationale for combination therapy with chemotherapeutic agents. Int J Cancer 61:409-15
Yellin, S A; Davidson, B J; Pinto, J T et al. (1994) Relationship of glutathione and glutathione-S-transferase to cisplatin sensitivity in human head and neck squamous carcinoma cell lines. Cancer Lett 85:223-32
Sturgis, E M; Sacks, P G; Masui, H et al. (1994) Effects of antiepidermal growth factor receptor antibody 528 on the proliferation and differentiation of head and neck cancer. Otolaryngol Head Neck Surg 111:633-43
Zou, C P; Clifford, J L; Xu, X C et al. (1994) Modulation by retinoic acid (RA) of squamous cell differentiation, cellular RA-binding proteins, and nuclear RA receptors in human head and neck squamous cell carcinoma cell lines. Cancer Res 54:5479-87
Sacks, P G; Racz, T; Schantz, S P et al. (1994) Growth inhibition by interferon beta and gamma of MDA 886Ln monolayer cells and multicellular tumor spheroids. A differentiation therapy model for squamous cell carcinoma. Arch Otolaryngol Head Neck Surg 120:1267-72
Sacks, P G; Oke, V; Mehta, K (1992) Antiproliferative effects of free and liposome-encapsulated retinoic acid in a squamous carcinoma model: monolayer cells and multicellular tumor spheroids. J Cancer Res Clin Oncol 118:490-6